Related references
Note: Only part of the references are listed.High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
A. Romano et al.
SCIENTIFIC REPORTS (2020)
Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma
Elisabet E. Manasanch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Cristina Perez et al.
BLOOD (2020)
Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone.
Claudio Cerchione et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Oksana Zavidij et al.
NATURE CANCER (2020)
Neutrophil-Derived MRP14 Supports Plasma Cell Commitment and Protects Myeloma Cells from Apoptosis
Zhihong Zhao et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
Fabrizio Puglisi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Expression, Role, and Regulation of Neutrophil Fcγ Receptors
Yu Wang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Marina Silvia Parisi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
Pauline Gueneau et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a real-world study: Polish Myeloma Group experience
Grzegorz Charlinski et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy
Alessandra Romano et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
Yayoi Matsumura-Kimoto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Yawara Kawano et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Neutrophil CD64, TLR2 and TLR4 expression increases but phagocytic potential decreases during tuberculosis
Nancy J. Hilda et al.
TUBERCULOSIS (2018)
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Xavier Leleu et al.
ANNALS OF HEMATOLOGY (2018)
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Philippe Moreau et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma
Concetta Conticello et al.
FUTURE ONCOLOGY (2017)
Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects
Gayane Manukyan et al.
ONCOTARGET (2017)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy
Indu R. Ramachandran et al.
CANCER LETTERS (2016)
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
Cesarina Giallongo et al.
ONCOTARGET (2016)
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Jesus F. San Miguel et al.
HAEMATOLOGICA (2015)
The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi et al.
ONCOLOGIST (2015)
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Jesus F. San Miguel et al.
HAEMATOLOGICA (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2014)
Immunological Dysregulation in Multiple Myeloma Microenvironment
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64
Desmond A. McCarthy et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Differentiation of polymorphonuclear neutrophils in patients with systemic infections and chronic inflammatory diseases: evidence of prolonged life span and de novo synthesis of fibronectin
C Wagner et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2000)
Share Paper
